Amgen’s third-quarter revenue rose 8%, and the company now projects 2026 revenue of $38.9 billion to $39.7 billion. It also raised its 2026 non-GAAP earnings-per-share outlook to $22.90 to $23.70. That gives investors something better than a good quarter alone: a stronger forecast from the company.
The distinction matters. Revenue growth tells you how the business performed in the quarter; guidance tells you what management expects next. A raised outlook is encouraging, but it remains a forecast, not money already in the bank.
IMDELLTRA stood out in the quarter as well. That makes it worth paying attention to, but one standout name doesn’t explain the entire 8% revenue increase. For stock pickers, the useful question is whether growth is spread across the business or depends heavily on a few bright spots.
There’s another wrinkle in that earnings range: it’s non-GAAP. Adjusted earnings can help investors compare operating performance, but they shouldn’t be mistaken for a complete picture of costs. The sensible move is to look at what the adjusted figure leaves out before treating the higher range as a clean win.
So where does Amgen go from here? Can it deliver on the new revenue range, and will IMDELLTRA remain a meaningful contributor? The raised forecast gives the business a higher bar to clear. That’s a better problem than cutting guidance, but it’s still a bar.
Play this story on TraderChamp
Follow AMGN (t/$AMGN) and talk it over with other players, then pick your five in the Game Arena.
